Ondansetron Carinopharm

Ondansetron, the active ingredient in Ondansetron Carinopharm, is a 5-HT3 receptor antagonist presented as an injectable solution for intramuscular, intravenous use. It prevents and treats chemotherapy‑induced, radiotherapy‑induced, and postoperative nausea and vomiting in patients undergoing these therapies.

GNH USA supplies Ondansetron Carinopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron acts on serotonin‑mediated pathways that trigger nausea and vomiting, making it valuable in several clinical settings. - Chemotherapy‑induced nausea and vomiting: prevents and reduces nausea and vomiting associated with cytotoxic chemotherapy. - Radiotherapy‑induced nausea and vomiting: helps control nausea and vomiting caused by radiation therapy. - Postoperative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures.

Ondansetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling of tiredness or lack of energy.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmia. - Severe allergic reaction (anaphylaxis): includes rash, swelling, breathing difficulty. - Serotonin syndrome: rare but potentially life‑threatening condition when combined with other serotonergic agents.

Before initiating therapy, consider the following safety measures. - Assess cardiac risk: evaluate QT interval and correct electrolyte imbalances. - Monitor electrolytes: treat hypokalemia, hypomagnesemia, and hypocalcemia. - Use with caution in hepatic impairment: dose adjustment may be required. - Avoid concomitant QT‑prolonging drugs: assess cumulative risk. - Pregnancy and lactation: weigh benefits against potential risks; limited data available. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Ondansetron may interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Other QT‑prolonging agents: increased risk of cardiac arrhythmia. - Apomorphine: may cause severe hypotension and loss of consciousness.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce ondansetron effectiveness. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): monitor for serotonin syndrome.